

July 15, 2016

To Whom It May Concern:

Company Name: Taisho Pharmaceutical Holdings Co., Ltd
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara, Chief Executive Officer
(First Section of TSE: Code 4581)
Contact: Takashi Shibata, General Manager
Corporate Communications
(Tel:+81-3985-1115)

Signing of Licensing and Commercialization Agreement
Regarding OTC Drug Products in Japan for the Allergy Treatment Claritin

Taisho Pharmaceutical Holdings Co., Ltd. (“Taisho Holdings”) has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. [Headquarters: Toshima-ku, Tokyo, CEO: Shigeru Uehara] (“Taisho Pharmaceutical”) and Bayer Yakuhin, Ltd. (“Bayer Yakuhin”) signed an agreement on July 11, 2016 regarding OTC drug products in Japan for the allergy treatment Claritin (Licensing and Commercialization Agreement).

Claritin is an allergy treatment that has a long-acting effect with selective peripheral histamine H1-receptor antagonistic activity. It is marketed in more than 123 countries around the world (as of January 2015). Additionally, in Japan, it has been sold as a prescription pharmaceutical since 2002.

According to the Practical Guideline for the Management of Allergic Rhinitis in Japan (PG-MARJ 2016) issued by the Japanese Society of Allergology, it has become clear that every two in five people in Japan suffer from allergic rhinitis. The number of people with allergic rhinitis in Japan has increased by 10% over the past 10 years.

Through Claritin, which is owned by Bayer, one of the top corporate groups in the global OTC drug industry, Taisho Pharmaceutical aims to provide people in Japan who suffer from allergic disorders with an effective, safe and convenient treatment option for allergic rhinitis.

The agreement will have a negligible impact on the consolidated business results of Taisho Pharmaceutical Holdings Co., Ltd.